FC2ブログ
2020年07月/ 06月≪ 12345678910111213141516171819202122232425262728293031≫08月
2019年11月30日(土)

11/29のツイートまとめ 

silly_fish

@AdCuius So now I can't trust the reg to be scientifically sound.For 2. harm reduction and 3. stay out of sex or gender, I would reply later.side note: Ovotesticular DSD, 1 of 4 specific conditions covered, comes in various karyotypes include 46,XX. So XX females might not be 100% safe.
11-29 05:12

@AdCuius 1-4. The research I'm referring to, which were funded by IAAF, might ignored the standard ethics code for medical research. The data were initially collected for doping control and are sensitive informations, so they might had to obtain participants' consent for diversion.
11-29 04:51

@AdCuius 1-3. The disciplines showed positive correlation between testosterone level and performance, aren't same with disciplines currently under restriction. CAS asked not to apply the reg for disciplines with no evidences of advantage, until it can establish one. But IAAF refused.
11-29 04:39

@AdCuius Apparently their conclusion was, elevated testosterone level confers performance advantage to women, regardless of their karyotypes. So there is no good reason to only target hyperandrogenic XY females. Dropping hyperandrogenism in XX females from regulation doesn't make sense.
11-29 04:25

@AdCuius 1-2. That research does not tell whether XY females enjoy the advantage hyperandrogenism gives them, differently from XX females do, or not. Because most participants were perisex, and the researchers carved out all the data from intersex/DSD participants while data collection.
11-29 04:12

@AdCuius As for 1. science; 1-1. The reg is established based on a research, witch showed performance improvement in female athletes with elevated testosterone level in certain disciplines. And its date were severely flawed. https://t.co/V6i5NLOUo7
11-29 04:01

スポンサーサイト



【編集】 |  04:18 |  ファイル倉庫  | TB(0)  | CM(0) | Top↑

Comment

コメントを投稿する

URL
コメント
パス  編集・削除するのに必要
非公開  管理者だけにコメントを表示
 

トラックバック

この記事のトラックバックURL

この記事へのトラックバック

 | HOME |